A Randomized, Open-Label, Comparative 3-way Treatment Crossover Study of 24-hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-using patients
Study identifier:D9612L00063
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
-
Medical condition
Heartburn
Phase
Phase 4
Healthy volunteers
No
Study drug
Esomeprazole, Lansoprazole, Pantoprazole
Sex
All
Actual Enrollment
100
Study type
Interventional
Age
18 Years - 60 Years
Date
Study Start Date: 01 Jun 2004
Primary Completion Date: 01 Nov 2004
Study Completion Date: 01 Nov 2004
Study design
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Oral | Drug: Esomeprazole 40mg Oral Other Name: Nexium |
| Experimental: 2 Oral | Drug: Lansoprazole 30mg Oral Other Name: Prevacid |
| Experimental: 3 Oral | Drug: Pantoprazole 40mg Oral Other Name: Protonix |
Contacts
Investigators
Principal Investigator
Paula Fernstrom
Nexium Global Product Director, AstraZeneca
